About Kronos Bio
Kronos Bio is a company based in San Mateo (United States) founded in 2017 was acquired by Concentra Biosciences in May 2025. Kronos Bio has raised $271.01 million across 3 funding rounds from investors including Fidelity Investments, BlackRock and Citadel. The company has 97 employees as of December 31, 2022. Kronos Bio operates in a competitive market with competitors including Sana Biotechnology, Janux Therapeutics, GigaGen, Carisma Therapeutics and Asher Biotherapeutics, among others.
- Headquarter San Mateo, United States
- Employees 97 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Kronos Bio, Inc.
-
Annual Revenue
$9.85 M (USD)57as on Dec 31, 2024
-
Net Profit
-$86.08 M (USD)24as on Dec 31, 2024
-
EBITDA
-$92.89 M (USD)24as on Dec 31, 2024
-
Total Equity Funding
$271.01 M (USD)
in 3 rounds
-
Latest Funding Round
$148 M (USD), Series B
Aug 24, 2020
-
Investors
Fidelity Investments
& 19 more
-
Employee Count
97
as on Dec 31, 2022
-
Acquired by
Concentra Biosciences
(May 01, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Kronos Bio
Unlock access to complete
Unlock access to complete
Funding Insights of Kronos Bio
Kronos Bio has successfully raised a total of $271.01M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $148 million completed in August 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Kronos Bio
Kronos Bio has secured backing from 20 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Fidelity Investments, BlackRock and Citadel.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Health-tech companies are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
Venture capital is provided to healthcare startups by Commodore Capital.
|
Locked | Locked | Locked | |
|
Investing in Life Sciences sectors like Healthcare and Biotechnology.
|
Locked | Locked | Locked |
Investor details for Kronos Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Kronos Bio
Investment portfolio details for Kronos Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Kronos Bio
Detailed financials for Kronos Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Kronos Bio Comparisons
Peer comparison for Kronos Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Kronos Bio
Kronos Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sana Biotechnology, Janux Therapeutics, GigaGen, Carisma Therapeutics and Asher Biotherapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Immunotherapeutics for cancer treatment are developed to target solid tumors.
|
|
| Locked | Locked | Locked |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms.
|
|
| Locked | Locked | Locked |
Chimeric antigen receptor macrophages are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Developer of immunotherapies for the treatment of cancer and autoimmune diseases
|
Detailed competitors of Kronos Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Kronos Bio
Complete news archive for Kronos Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kronos Bio
Kronos Bio was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Kronos Bio is headquartered in San Mateo, United States. It is registered at San Mateo, California, United States.
Kronos Bio is a funded company, having raised a total of $271.01M across 3 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Kronos Bio is 97.
Annual revenue of Kronos Bio is $9.85M as on Dec 31, 2024.
Kronos Bio was founded in 2017 and is based in San Mateo, United States. Operations focus on the biotechnology sector, where small molecule-based therapeutics are created to address cancer. These molecules are designed to bind directly to target proteins, interfere with their activity, disrupt protein-protein complexes, or influence adjacent proteins for indirect modulation. The companys domain is kronosbio.com.
Kronos Bio's top competitors include Janux Therapeutics, Sana Biotechnology and GigaGen.
Kronos Bio has 20 investors. Key investors include Fidelity Investments, BlackRock, Citadel, Perceptive Advisors, and Commodore Capital.